



PATENT
ATTORNEY DOCKET NO.: 053665-5012-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Louis S. KUCERA et al.

Confirmation No.: To Be Assigned

Application No.: 10/781,894

Group Art Unit: To Be Assigned

Filed: February 20, 2004

Examiner: To Be Assigned

For: METHODS AND COMPOSITIONS
FOR THE TREATMENT OF
RESPIRATORY SYNCTIAL VIRUS

Attorney Docket No.: 053665-5012-00

INFORMATION DISCLOSURE STATEMENT

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

Pursuant to Applicants' duty of disclosure under 37 C.F.R. § 1.97 and 1.98, enclosed is a Form PTO-1449 which lists 190 references. Copies of the foreign patent documents and other references are enclosed for the Examiner's convenience. Pursuant to the rules pertaining to applications filed after June 30, 2003, copies of the U.S. references are not enclosed.

It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the Form PTO-1449.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b); before the mailing of the first Office action on the merits in the application. No fee is believed to be due for this submission. If the U.S. Patent and Trademark Office deems a fee is due, please charge this fee and any other required fees to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: May 14, 2004

By:


Paul E. Dietze Reg. No. 45,627

CUSTOMER NO. 09629
MORGAN, LEWIS & BOCKIUS LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Telephone: (202) 739-3000
Facsimile: (202) 739-3001

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE February 20, 2004	GROUP To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2,086,585	07/13/1937	Taub et al.	260	127	
	A02	2,087,132	07/13/1937	Taub et al.	260	127	
	A03	2,108,765	02/15/1938	Domagk	167	30	
	A04	2,209,383	07/30/1940	Bock	8	116	
	A05	2,439,969	04/20/1948	Fourneau	260	338	
	A06	2,445,393	07/20/1948	Fourneau	260	338	
	A07	2,513,747	07/04/1950	Sallman et al.	260	338	
	A08	2,606,909	08/12/1952	Blicke	260	338	
	A09	2,689,790	09/21/1954	Mowry et al.	71	2.7	
	A10	2,950,253	08/23/1960	Kling et al.	252	152	
	A11	3,054,678	09/18/1962	Michener et al.	99	150	
	A12	3,694,473	09/26/1972	Eibl et al.	260	403	
	A13	4,093,714	06/06/1978	Tolman et al.	424	180	
	A14	4,096,278	06/20/1978	Queuille	424	329	
	A15	4,119,714	10/10/1978	Kny et al.	424	199	
	A16	4,159,988	07/03/1979	Eibl et al.	260	340.9R	
	A17	4,235,877	11/25/1980	Fullerton	424	89	
	A18	4,329,302	05/11/1982	Hanahan et al.	260	925	
	A19	4,426,525	01/17/1984	Hozumi et al.	546	22	
	A20	4,444,766	04/24/1984	Bosies et al.	424	211	
	A21	4,471,113	09/11/1984	MacCoss	536	29	
	A22	4,540,521	09/10/1985	Garst et al.	260	459	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. 053665-5012-00		APPLICATION NO 10/781,894	
				APPLICANT Louis S. KUCERA et al.			
				FILING DATE. February 20, 2004		GROUP To Be Assigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	A	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A23	4,619,917	10/28/1986	Lee et al.	514	77	
	A24	4,661,509	04/28/1987	Gordon et al.	514	397	
	A25	4,816,450	03/28/1989	Bell et al.	514	25	
	A26	4,826,823	05/02/1989	Cook et al.	514	46	
	A27	4,835,263	05/30/1989	Nguyen et al.	536	27	
	A28	4,837,023	06/06/1989	Eibl	424	439	
	A29	4,841,039	06/20/1989	Chu et al.	536	29	
	A30	4,880,782	11/14/1989	Eckstein et al.	514	45	
	A31	5,026,687	6/25/1991	Yarchoan et al.	514	45	
	A32	5,034,394	07/23/1991	Daluge	514	261	
	A33	5,138,045	08/11/1992	Cook et al.	536	27	
	A34	5,496,546	03/05/1996	Wang et al.	424	78.36	
	A35	5,614,548	03/25/1997	Piantadosi et al.	514	440	
	A36	5,633,388	05/27/1997	Diana et al.	548	305.7	
	A37	5,770,584	06/23/1998	Kucera et al.	514	77	
	A38	5,830,905	11/03/1998	Diana et al.	514	322	
	A39	5,846,964	12/08/1998	Ozeki	514	182	
	A40	5,891,874	04/06/1999	Colacino et al.	514	234.5	
	A41	5,922,757	07/13/1999	Chojkier	514	458	
	A42	5,962,437	10/05/1999	Kucera et al.	514	77	
	A43	6,034,134	03/07/2000	Gold et al.	514	579	
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	0 094 586	11/23/1983	EPO (English)				
	B02	0 109 255	05/23/1984	EPO (English)				
	B03	0 142 333	05/22/1985	EPO (English)				
	B04	0 145 303	06/19/1985	EPO (English)				
	B05	0 146 258	06/26/1985	EPO (English)				
	B06	0 252 310	01/13/1988	EPO				X
	B07	0 310 109	04/05/1989	EPO (English)				
	B08	0 335 396	04/10/1989	EPO (English)				
	B09	0 348 859	01/03/1990	EPO (English)				
	B10	0 416 401	03/13/1991	EPO			X Abs	
	B11	0 434 450	06/26/1991	EPO (English)				
	B12	0 506 704	07/11/1991	EPO				
	B13	0 632 048	01/04/1995	EPO (English)				
	B14	1,561,630	03/28/1969	France			X Abs	
	B15	199 14 474	10/07/1999	Germany			X Abs	
	B16	37 26 945 A1	02/23/1989	Germany			X Abs	
	B17	39 34 820 A1	04/25/1991	Germany			X Abs	
	B18	40 10 228 A1	10/02/1991	Germany			X Abs	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 053665-5012-00	APPLICATION NO 10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE February 20, 2004	GROUP To Be Assigned

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B19	1029319	01/31/1989	Japan			X Abs	
	B20	49-100224	09/21/1974	Japan				X
	B21	08-268890	10/15/1996	Japan			X Abs	
	B22	10-101591	04/21/1998	Japan			X Abs	
	B23	90/05736	05/31/1990	WIPO (English)				
	B24	90/15601	12/20/1990	WIPO (English)				
	B25	91/05558	05/02/1991	WIPO			X Abs	
	B26	91/09602	07/11/1991	WIPO			X Abs	
	B27	91/18914	12/12/1991	WIPO (English)				
	B28	92/03462	03/05/1992	WIPO			X Abs	
	B29	92/06192	04/16/1992	WIPO (English)				
	B30	93/08807	05/13/1993	WIPO (English)				
	B31	93/16091	08/19/1993	WIPO			X Abs	
	B32	93/16092	08/19/1993	WIPO			X Abs	
	B33	93/17020	09/02/1993	WIPO (English)				
	B34	93/21191	10/28/1993	WIPO (English)				
	B35	WO 98/22496	5/28/1998	WIPO (English)				
	B36	WO 98/17679	4/30/1998	WIPO (English)				
	B37	WO 99/07734	2/18/1999	WIPO (English)				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Aggarwal, S. K. et al., "Synthesis and Biological Evaluation of Prodrugs of Zidovudine", <u>J. Med. Chem.</u> , 33, 1505-10 (1990)
C02	Alt M. et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation", <u>Archives of Virology</u> 142:589-599, 1997
C03	Alt M. et al., "Specific Inhibition of Hepatitis C Viral Gene Expression by Antisense Phosphorothioate Oligodeoxynucleotides", <u>Hepatology</u> 22:707-717, September 1995
C04	Anderson, L. J. et al., "Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies", <u>Journal of Infectious Diseases</u> , 151:626-633 (April 1985)
C05	Attwood, M. R. et al., "The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase", <u>Antiviral Chemistry and Chemotherapy</u> 10:259-273, September 1999
C06	Battaglia, A.M. et al., "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <u>The Annals of Pharmacotherapy</u> 34:487-494, April 2000
C07	Berenguer, M. et al., "Hepatitis C Virus in the Transplant Setting", <u>Antiviral Therapy</u> 3(Suppl. 3):125-136, 1998
C08	Boldanova, N. B. et al., "Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis", <u>Vopr. Med. Khim.</u> , 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986)
C09	Bosies, E. et al., "Preparation of Lecithin Analogs as Retrovirucides and Virucides", Chemical Abstracts, <u>115CA</u> ; 72142p 1991
C10	Chu M. et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus <i>Penicillium Griseofulvum</i> ", <u>Bioorganic and Medicinal Chemistry Letters</u> 9:1949-1952
C11	Chu M. et al., "Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from <i>Streptomyces</i> sp.", <u>Tetrahedron Letters</u> 37:7229-7232, 1996
C12	Cooper, K. E., "The Effectiveness of Ribavirin in the Treatment of RSV", <u>Pediatric Nursing</u> , January-February 2001, 27:95-98
C13	Crompton, S. et al., "Novel Lipid Analogs with Cytostatic and Cytocidal Activity", <u>Anticancer Research</u> , Vol. 8, No. 6, pp. 1361-1366 (Nov.-Dec. 1988)
C14	Daniel, L. W. et al., "Alkyl-Linked Diglycerides Inhibit Protein Kinase C Activation by Diacylglycerols", <u>Biochemical & Biophysical Research Communications</u> , 151, 291-97 (Feb. 29, 1988)
C15	Dietzfelbinger, "Cytotoxic and Purging Effects of ET-18-OCH3 in Human Malignant Lymphoid Cell Lines in Vitro", Abstract 2472, <u>Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)
C16	Domawchowske J. B. et al., "Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis and Treatment", <u>Clinical Microbiology Reviews</u> , 12:298-309 (April 1999)
C17	Englund, J. A., "Prevention Strategies for Respiratory Syncytial Virus: Passive and Active Immunization", <u>J. Pediatr.</u> , August 1999, 135:38-44
C18	Falsey A. R. et al., "Acute Respiratory Tract Infection in Daycare Centers for Older Persons", <u>J Am Geriatric Soc.</u> , 1995; 43:30-36
C19	Falsey A. R. et al., "Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings", <u>J Am Geriatr Soc.</u> , 1992; 40:115-119
C20	Fields, A. P. et al., "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor", <u>Nature</u> , 333, 278-80 (19 May 1988)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C21	Galderisi U. et al., "Antisense Oligonucleotides as Therapeutic Agents", <u>Journal of Cellular Physiology</u> , 181:251-257, 1999
C22	Garzon L. S. et al., "Management of Respiratory Syncytial Virus with Lower Respiratory Tract Infection in Infants and Children", <u>AACN Clinical Issues</u> , 2002, 13:421-430
C23	Glezen W. P. et al., "Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus", <u>Am J Dis Child</u> , 1986, 140:543-546
C24	Graham, F. L. et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5-DNA", <u>Virology</u> , Vol. 52, pp. 456-467, 1973
C25	Greenough, <u>Acta. Paediatr. Suppl.</u> , 436:11-14 (2001)
C26	Gueguierian, A. et al., "Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis: a Randomized, Placebo-Controlled Trial", <u>Am J Resp Crit Care Med.</u> , 1999, 160:829-834
C27	Hacking, D. et al., "Respiratory Syncytial Virus - Virus Biology and the Host Response", <u>Journal of Infection</u> , 2002, 45:18-24
C28	Hall C. B. et al., "Infectivity of Respiratory Syncytial Virus by Various Routes of Inoculation", <u>Infect Immun.</u> , 1981, 33:779-783
C29	Hall, C. B. et al., "Nosocomial Respiratory Syncytial Virus Infections", <u>N Engl J Med.</u> , 1975, 293:1343-1346
C30	Hall C. B. et al., "Respiratory Syncytial Virus Infections in Previously Healthy Working Adults", <u>Clin Infect Dis.</u> , September 15, 2001, 33:792-796
C31	Hall C. B. et al., "Respiratory Syncytial Virus Infections Within Families", <u>N Engl J Med</u> , 1976, 294:414-419
C32	Hall, C. B., "Respiratory Syncytial Virus and Parainfluenza Virus", <u>N. Engl. J. Med.</u> , 344:1917-1928 (June 21, 2001)
C33	Harada, S. et al., "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay", <u>Science</u> , 229, 563-566 (9 Aug. 1985)
C34	Henderson, F.W. et al., "Respiratory-Syncytial-Virus Infections, Reinfections, and Immunity: a Prospective, Longitudinal Study in Young Children", <u>N Engl J Med</u> , 1979, 300:530-534
C35	Himmelmann, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro", <u>Abstract 2448, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)
C36	Hirsch, M. S. et al., "Antiviral Agents", <u>Fields Virology</u> , Third edition, Lippincott, Raven Publishers, page 431-466, 1996
C37	Hruska, J. F. et al., "In vivo Inhibition of Respiratory Syncytial Virus by Ribavirin", <u>Antimicrob Agents Chemother.</u> , 1982, 21:125-130
C38	Hsu, L. et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides", <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, (1992)
C39	IMPACT RSV Study Group, "Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants", <u>Pediatrics</u> , 1998, 102:531-537
C40	Kakiuchi N. et al., "Non-peptide Inhibitors of HCV Serine Proteinase", <u>J. FEBS Letters</u> 421:217-220
C41	Kasnar, B. et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'-Dideoxy-Pyridazine Nucleosides as Potential Antiviral Agents", <u>Nucleosides & Nucleotides</u> , 13(1-3), pp. 459-479, (1994)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE February 20, 2004	GROUP To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
C42	Kawana, F. et al., "Inhibitory Effects of Antiviral Compounds on Respiratory Syncytial Virus Replication In Vitro", <u>Antimicrob Agents Chemother.</u> , August 31, 1987, (8):1225-30	
C43	Kimpen et al., <u>Respiratory Research</u> , Vol. 3, Suppl. 1, pp. S40-45 (2002)	
C44	Korba, B. E. et al., "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication", <u>Antiviral Research</u> , 19, 55-70 (1992)	
C45	Krugner-Higby, L., et al., "Membrane-Interactive Phospholipids Inhibit HIV Type 1-Induced Cell Fusion and Surface gp160/gp120 Binding to Monoclonal Antibody", <u>AIDS Research and Human Retroviruses</u> , Vol. 11, 705-712, (1995)	
C46	Krugner-Higby, L. A. et al., "Novel Membrane Interactive Ether Lipid Analogs Inhibit HIV-1 Glycoprotein Interaction with CD4 ⁺ Cells", Abstract 321, <u>32nd Interscience Conf. on Antimicrobial Agents and Chemotherapy</u> , Anaheim, 164, (11-14 Oct. 1992)	
C47	Kucera, L. S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2", <u>Aids Research and Human Retroviruses</u> , Vol. 9, No. 4, pp. 307-314, (1993)	
C48	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodeficiency Virus Production Measured by Plaque Assay", <u>Annals of the New York Academy of Sciences</u> , 545-548 (26 Dec. 1990)	
C49	Kucera, "Inhibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Lipid Analogs" <u>International Conference on AIDS, Abstract No. W.C.O. 21</u> , June 4-9, 1989, p. 528	
C50	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Lipids", Abstract No. 2470, <u>Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)	
C51	Kucera, L., et al., "Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion by Synthetic Phospholipid Analogs", <u>Antiviral Research</u> , p. A260 (1985)	
C52	Kucera, "Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of HIV-1 Induces Glycoproteins and Inhibit Pathogenesis", Abstract, <u>Innovations in Therapy of Human Viral Diseases, Symposium, Research Triangle Park</u> , 16, (6-9 Dec. 1992)	
C53	Kucera, L.S. et al., " <i>In Vitro</i> Evaluation and Characterization of Newly Designed Alkylamidophospholipid Analogues as Anti-Human Immunodeficiency Virus Type 1 Agents", <u>Antiviral Chemistry and Chemotherapy</u> , 1998; 9:157-165	
C54	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity", Abstract, <u>ICAAC Orlando</u> , (1994)	
C55	Kucera, L. et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", <u>AIDS Research And Human Retroviruses</u> , 6, 491-501, (1990)	
C56	Kucera, L. S. et al., "Synthesis and Evaluation of a Novel Synthetic Phosphocholine Lipid-AZT Conjugate that Double-Targets Wild-Type and Drug Resistant Variants of HIV", <u>Nucleosides, Nucleotides and Nucleic Acids</u> , 23:385-399 (2004)	
C57	Kumar, R., et al., "Equal Inhibition of HIV Replication by Stereoisomers of Phosphatidyl-Azidothymidine – Lack of Stereospecificity of Lysosomal Phospholipase A ₁ ", <u>The Journal of Biological Chemistry</u> , 267, 20288-20292, (1992)	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C58	Maccjak, D. J. et al., "Inhibition of Viral Replication by Nuclease Resistant Hammerhead Birozymes Directed Against Hepatitis C virus RNA", <u>Hepatology</u> , 30 Abstract 995, 1999
C59	Marasco, Jr., C. J., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors of Protein Kinase C Activity, Neoplastic Cell Growth, and HIV-1 Infectivity", <u>Dissertation for Ph.D., Univ. of No. Carolina, Chapel Hill</u> , 1990
C60	Marasco, C. J. et al., "Synthesis and Biological Activity of Novel Quaternary Ammonium Derivatives of Alkylglycerols as Potent Inhibitors of Protein Kinase C", <u>Journal of Medicinal Chemistry</u> , No. 33, pp. 985-992 (March 1990)
C61	Marasco et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C", <u>American Assoc. of Pharmaceutical Scientists Abstract</u> , Orlando, FL, (1993)
C62	Marx, M. H. et al., "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-Phosphocholine", <u>Journal of Medicinal Chemistry</u> , 31, 858-863 (March 28, 1988)
C63	Meert, K. L. et al., "Aerosolized Ribavirin in Mechanically Ventilated Children with Respiratory Syncytial Virus Lower Respiratory Tract Disease: a Prospective Double-Blind Randomized Trial", <u>Crit Care Med.</u> , April 1994, 22:566-572
C64	Meyer, K. L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents", <u>J. Med. Chem.</u> , 34, 1377-1383, (1991)
C65	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids", <u>AAPS Meeting, Atlanta Abstract N. MN-510</u> , p. S-41, (22-25 Oct. 1989)
C66	Miller, R. H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses", <u>Proc. Natl. Acad. Sci. USA</u> , 83, pp. 2531-2535, (April 1986)
C67	Mitsuya, H. et al., "Strategies for Antiviral Therapy in AIDS", <u>Nature</u> , 325, 773-78 (26 February 1987)
C68	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs", <u>Abstract 2471, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 Abstract 2471 (March 1990)
C69	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia", <u>Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics</u> , Vol. 31, pp. 416, Abstract 2467, (March 1990)
C70	Modest, E. J. et al., "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs", <u>The Pharmacological Effect of Lipids III: Role of Lipids in Cancer Research</u> , (IN PRESS), pp. 330-337 (1989)
C71	Molla, A. et al., "Human Serum Attenuates the Activity of Protease Inhibitors Toward Wild-Type and Mutant Human Immunodeficiency Virus", <u>Virology</u> , 1998, 250:255-262
C72	Morrey, J. D. et al., "Effects of Zidovudine on Friend Virus Complex Infection in Rfv-3 ^{7/8} Genotype-Containing Mice Used as a Model for HIV Infection", <u>Journal of Acquired Immune Deficiency Syndromes</u> , 3, 500-10 (1990)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C73	Morris-Natschke, S. L. et al., "Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of <i>in Vitro</i> Antineoplastic Activity", <u>J. Med. Chem.</u> , 36:2018-2025 (1993)
C74	Morris-Natschke, S. et al. "Synthesis of Sulfur Analogues of Alkyl Lysophosphospholipid and Neoplastic Cell Growth Inhibitory Properties", <u>J. of Med. Chem.</u> , 29, 2114-17 (1986)
C75	Mutson, M. A. et al., "Two Distinct Subtypes of Human Respiratory Syncytial Virus", <u>The Journal of General Virology</u> , 66:2111-2124 (October 1985)
C76	Nara, P. L. et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing Antibody", <u>AIDS Research and Human Retroviruses</u> , 3, 283-302 (1987)
C77	Nosedá, A. et al., " <i>In Vitro</i> Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells", <u>Cancer Research</u> , 48, 1788-1791 (April 1, 1988)
C78	Nosedá, A. et al., "Neoplastic Cell Inhibition with New Ether Lipids Analogs", <u>Lipids</u> , 22, 878-883 (Nov. 1987)
C79	Ostertag, W. et al., "Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus", <u>Proc. Nat. Acad. Sci. USA</u> , 71, 4980-85 (Dec. 1974)
C80	Ouyang H., et al., "Structure-Activity Relationship for Enhancement of Paracellular Permeability Across Caco-2 Cell Monolayers by 3-Alkylamido-2-alkoxypropylphosphocholines", <u>J. Med. Chem.</u> , 45:2857-2866 (2002)
C81	Pacheco, D. Y. et al., "Mechanisms of Toxicity of Hepsulfam in Human Tumor Cell Lines", Abstract 2446, <u>Proceedings of the American Association for Cancer Research</u> , 81, 412 (May 1990)
C82	Piantadosi, C. et al., "Synthesis and Evaluation of Novel Ether Lipid Nucleoside Conjugates for Anti-HIV-1 Activity", <u>J. Med. Chem.</u> , 34, 1408-14 (1991)
C83	Pidgeon C. et al., "Novel Acylated Phospholipid Drugs for AIDS", <u>Chemical Abstract</u> , 120:69591, (1994)
C84	Piedimonte, G., "The Association Between Respiratory Syncytial Virus Infection and Reactive Airway Disease", <u>Respiratory Medicine</u> , 2002, 96 (Suppl B), S25-S29
C85	The PREVENT Study Group, "Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis", <u>Pediatrics</u> , 1997, 99:93-99
C86	Prince, G. A., "The Pathogenesis of Respiratory Syncytial Virus Infection in Cotton Rats", <u>Am J Pathol.</u> , 1978, 93:771-91
C87	Qasim M.A. et al. "Interscaffolding Additivity. Association of P ₁ Variants of Eglin c and of Turkey Ovomuroid Third Domain with Serine Proteinases", <u>Biochemistry</u> 36:1598-1607, 1997
C88	Rodriguez, W. J. et al., "Prospective Follow-Up and Pulmonary Functions from a Placebo-Controlled Randomized Trial of Ribavirin Therapy in Respiratory Syncytial Virus Bronchiolitis", <u>Arch Pediatr Adolesc Med</u> , May 1999, 153:469-474
C89	Sable, C. A. et al., "Orthomyxoviral and Paramyxoviral Infections in Transplant Patients", <u>Infect Dis Clin North Am</u> , December 1995, 9:987-1003
C90	Sarin, P. S. et al., "Effects of a Novel Compound (AL 721) on HTLV-III Infectivity in Vitro", <u>The New England Journal of Medicine</u> , Vol. 313, 1289-90 (Nov. 14, 1985),

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	053665-5012-00	10/781,894
	APPLICANT Louis S. KUCERA et al.	
	FILING DATE	GROUP
	February 20, 2004	To Be Assigned

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C91	Scolaro M. J. et al., "Inhibition of Virus Replication with Oligonucleotides", <u>Chemical Abstracts</u> , 117:124476, (1992)
C92	Siquers, N. et al., "Respiratory Syncytial Virus Bronchiolitis in Infancy is an Important Risk Factor for Asthma and Allergy at Age 7", <u>American Journal of Respiratory and Critical Care Medicine</u> , 161:1501-1507 (May 2000)
C93	Small, "Characterization of Cells Sensitive and Resistant to ET-18-OCH ₃ ", <u>Abstract 2447, Proceedings of the American Assoc. for Cancer Res.</u> , 31, 416 (March 1990)
C94	Smith, D. W. et al., "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection", <u>New England Journal of Medicine</u> , July 1991, 325:24-29
C95	Staat, M.A., "Respiratory Syncytial Virus Infections in Children", <u>Seminars in Respiratory Infections</u> , March 2002, 17:15-20
C96	Sudo K. et al, <u>Antiviral Chemistry and Chemotherapy</u> 9:186, 1998
C97	Sudo K. et al., "Establishment of an In Vitro System for Screening Hepatitis C Virus Protease Inhibitors Using High Performance Liquid Chromatography", <u>Antiviral Research</u> 32:9-18, 1996
C98	Sunamoto, J. et al., "Induction of Cytotoxic T Cell", <u>Chemical Abstracts</u> , 117:68365, (1992)
C99	Surles, J. R. et al, "Multigram Synthesis of 1-Alkylamido Phospholipids", <u>Lipids</u> , 28, 55-57
C100	Swayze, E. E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative R82150, With Activity Against Human Immunodeficiency Virus", <u>Bioorganic & Medical Chemistry Letters</u> , Vol. 3, No. 4, pp 543-546, (1993)
C101	Takeshita N. et al., "An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus Proteinase", <u>Analytical Biochemistry</u> 247:242-246, May 1, 1997
C102	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Cell Fusion", <u>Abstracts of the 2nd National Conference on Human Retroviruses</u> , Session 18, (1995)
C103	Tiollais, P., et al., "Hepatitis B. Virus", <u>Scientific American</u> , 116-123, (April 1991)
C104	Van Wijk, G. M. et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride", <u>Biochemistry</u> , 31, 5912-5917, (June 30, 1992)
C105	Vos, G. D. et al., "Treatment of Respiratory Failure Due to Respiratory Syncytial Virus Pneumonia with Natural Surfactant", <u>Pediatr Pulmonol.</u> , December 1996, 22:412-415
C106	Wang, E. E. et al., "Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Prospective Study of Risk Factors and Outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory Tract Infection", <u>J Pediatr</u> , February 1995, 126:212-219
C107	Whimbey, E. et al., "Community Respiratory Virus Infections Among Hospitalized Adult Bone Marrow Transplant Recipients", <u>Clin Infect Dis.</u> , May 1996, 22:778-782
C108	Yamaue, H. et al., "Chemosensitivity Testing with Highly Purified Fresh Human Tumor Cells with the MTT Colorimetric Assay", <u>Eur J Cancer</u> , 1991, 27:1258-1263
C109	Yanagawa, H. et al. "Spontaneous Formation of Superhelical Strands", <u>Journal of the American Chemical Society</u> , 111, 4567-70 (June 21, 1989)
C110	Yarchoan, R. et al., "Therapeutic Strategies in the Treatment of AIDS", <u>Annual Reports in Medicinal Chemistry</u> , Vol. 23, 253-263 (1988)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	